Benzinga | Aug 27, 2021 06:20AM EDT

Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

* The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ:INCY) - MorphoSys AG's (NASDAQ:MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

* The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT).

* The conditional approval is based on the results from the L-MIND study that showed the best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%.

* Incyte has exclusive commercialization rights to tafasitamab outside the U.S.

* Related content: Benzinga's Full FDA Calendar

* Price Action: MOR shares traded 1.27% higher at $14.31 premarket Friday, and Incy shares closed 0.81% lower at $75.15 on Thursday.